Legal Representation
Attorney
Carlynn Beth Ferguson
USPTO Deadlines
Next Deadline
104 days remaining
Statement of Use Due - Extension 2 Granted
Due Date
November 14, 2025
Extension Available
Until May 14, 2025
Application History
45 eventsDate | Code | Type | Description | Documents |
---|---|---|---|---|
Mar 22, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
Mar 21, 2025 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
Mar 21, 2025 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
Mar 21, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
Jun 13, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
Jun 5, 2024 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
Jun 5, 2024 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
Jun 5, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
May 14, 2024 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
Mar 19, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
Mar 19, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
Feb 28, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
Feb 28, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
Feb 15, 2024 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
Feb 15, 2024 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
Feb 15, 2024 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
Feb 15, 2024 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | Loading... |
Feb 15, 2024 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
Nov 1, 2023 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED | Loading... |
Nov 1, 2023 | GNFR | O | FINAL REFUSAL E-MAILED | Loading... |
Nov 1, 2023 | CNFR | R | FINAL REFUSAL WRITTEN | Loading... |
Nov 1, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
Oct 31, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
Oct 31, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
Aug 15, 2023 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
Aug 15, 2023 | GNRT | O | NON-FINAL ACTION E-MAILED | Loading... |
Aug 15, 2023 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
Jul 21, 2023 | ZZZX | Z | PREVIOUS ALLOWANCE COUNT WITHDRAWN | Loading... |
Jul 11, 2023 | PBCR | Z | WITHDRAWN FROM PUB - OG REVIEW QUERY | Loading... |
Jun 29, 2023 | FIXD | O | ELECTRONIC RECORD REVIEW COMPLETE | Loading... |
Jun 23, 2023 | ERRR | O | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | Loading... |
Jun 22, 2023 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
Jun 22, 2023 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
Jun 22, 2023 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
Jun 22, 2023 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | Loading... |
Jun 22, 2023 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
May 20, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
May 19, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
May 19, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
Feb 27, 2023 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
Feb 27, 2023 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
Feb 27, 2023 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
Feb 16, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
May 4, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
May 3, 2022 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 001
Chemical and biological preparations for use in science and industry; Chemical and biological preparations for genetically modifying human and animal cells for non-medical purposes; reagents for use in the genetic modification of human and animal cells for scientific or medical research use; human and animal cells and parts in the nature of stem cells thereof for scientific and research purposes; T cells for scientific and research purposes; regulatory T cells for scientific and research purposes; preparations of blood or cells extracted from humans and animals for scientific and research purposes; chimeric antigen receptors and preparations thereof for scientific and research purposes; antibody reagents used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use for use in science and industry; nucleic acids for laboratory use; synthetic deoxyribonucleic acids for scientific purposes; viral vectors for use in science and industry; nucleic acid vectors for use in science and industry
Class 005
Pharmaceutical and biological preparations for diagnostic, medical, therapeutic and prophylactic use, namely for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; pharmaceutical, medical and veterinary preparations for diagnostic, therapeutic and prophylactic purposes, namely for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; pharmaceutical preparations for cell therapy; pharmaceutical preparations for gene therapy; pharmaceutical preparations for genetically modifying human and animal cells for diagnostic and medical purposes; human and animal cells and parts, namely stem cells thereof for medical and veterinary purposes; T cells for medical and veterinary purposes; regulatory T cells for medical and veterinary purposes; preparations of blood or cells extracted from humans and animals which have been adapted for therapeutic purposes; pharmaceutical, medical and clinical preparations for use in treatment, amelioration and prophylaxis of diseases, disorders and suppression of the immune system; immunological agents and preparations for medical purposes, namely for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; pharmaceutical preparations for therapies to modulate the immune system; pharmaceutical preparations for therapies for autoimmune conditions and immunological disorders; chimeric antigen receptors and therapeutic preparations for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; pharmaceutical preparations for therapeutic delivery of nucleic acids; viral vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; nucleic acid vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; medical pharmaceutical preparations containing viral vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection; medical preparations containing nucleic acid vectors for therapeutic and prophylactic purposes for the treatment of genetic, autoimmune and inflammatory diseases, disorders and deficiencies, and for preventing organ transplant rejection
Class 040
Pharmaceutical manufacturing and processing; biological, biotechnological and biopharmaceutical manufacturing and manufacturing processing; manufacturing processing of biological tissue, blood, cell and genetic material; viral vector production, namely manufacture; gene therapy production, namely manufacture; custom manufacture of pharmaceutical and biological formulations and products; processing and modification of human and animal cells in the custom manufacture of pharmaceutical and biological formulations and products
Classification
International Classes
001
005
040